--- a
+++ b/clusters/3009knumclusters/clust_85.txt
@@ -0,0 +1,624 @@
+Adequate organ function as defined per protocol
+Adequate organ function
+Adequate organ function
+Adequate major organ function
+Normal organ and marrow function:
+Adequate hematologic and end-organ function
+Have adequate organ function.
+Subject has adequate organ and marrow function.
+Adequate organ function
+Demonstrate adequate organ function as defined below:
+6. Adequate organ and marrow function;
+Adequate hematologic and end organ function
+Adequate hematologic and end-organ function
+Demonstrated adequate organ function within 14 days of Cycle 1 Day 1 (C1D1).
+Has adequate organ function
+Adequate organ function
+Demonstrate adequate organ function as evidenced by laboratory testing
+Adequate bone marrow and organ function, as defined by the protocol
+Adequate organ function as defined below:
+Adequate organ function as indicated by laboratory values
+Adequate organ function per protocol-defined criteria.
+Adequate organ function defined as follows:
+Adequate end-organ function
+Has adequate organ function.
+Adequate hematologic and end organ function based on laboratory results obtained within 14 days prior to initiation of study treatment;
+Adequate organ function at baseline .
+Adequate hematologic and end-organ function, defined by laboratory test results, obtained within 14 days before initiation of study treatment
+Adequate hematologic and end-organ function
+Patient must meet the organ function and system function requirements as stated in the protocol
+Adequate organ and bone marrow function:
+Adequate organ and marrow function
+Adequate organ and marrow function
+Adequate organ function as measured by various blood parameters
+Subject must have adequate organ function as defined below. The following parameters must be evaluated within 28 days prior to Cycle 0 Day 1 (monotherapy run-in period):
+Adequate hematologic and end organ function
+Have adequate organ function.
+Have adequate organ function, defined as:
+Demonstrates adequate organ function
+Must have adequate organ and marrow function
+Adequate organ function.
+Adequate organ function
+Adequate hematologic and end-organ function
+Adequate organ function
+Have adequate organ function
+Adequate hematological and organ function as confirmed by laboratory values
+Adequate organ function (defined by the following parameters):
+Adequate organ function
+Have adequate organ function, including:
+Patient with adequate organ functions
+Adequate organ function defined as follows:
+Have adequate organ function.
+Have adequate organ function.
+Adequate organ function as defined by and obtained within 28 days of starting treatment:
+Adequate organ function
+Adequate organ functions
+Poor organ function.
+Demonstrates adequate organ function.
+Adequate organ function, defined as follows:
+Adequate organ function.
+Subjects with adequate organ and marrow function
+Adequate hematologic and end-organ function Cancer-Related Inclusion Criteria:
+Participant has adequate bone marrow and organ function as defined by the following laboratory values:
+Patients must have adequate organ and bone marrow function within 14 days prior to registration, as defined below:
+Adequate hematologic and end-organ function
+Good organ function:
+Adequate organ function within 14 days of study registration (30 days for pulmonary and cardiac) as defined in section 4.5
+Adequate hematologic and organ function
+Must have adequate organ function.
+Demonstrates adequate organ function.
+Adequate hematologic and end-organ function
+Adequate organ function as defined by the following laboratory values at screening:
+Adequate organ function
+Adequate organ function
+Adequate bone marrow and organ function
+Adequate hematologic and organ function within 28 days before the first study treatment
+Has adequate organ function
+Poor vital organ function defined as:
+Adequate organ function defined as:
+Adequate hematologic and end organ function
+Adequate organ and marrow function as defined below:
+Have adequate organ function.
+Has adequate organ function.
+Have adequate normal organ and marrow function, including the following:
+Adequate organ function as determined by the following laboratory values:
+The patient has adequate baseline organ function, as demonstrated by the following:
+The patient has adequate organ and marrow function as follows:
+Organ Function Requirements:
+Adequate organ function within 14 days of study registration including:\r\n* Absolute lymphocyte count (ALC) >= 0.5 x 10^9/L
+Adequate organ function within 14 days of study registration including:\r\n* Platelets >= 100 x 10^9/L
+Adequate organ function within 14 days of study registration including:\r\n* Hemoglobin >= 8 g/dL
+Organ function:
+Subjects with adequate organ function as measured by:
+Adequate hematologic and end organ function
+adequate organ function
+Adequate organ system function.
+Patients must have adequate major organ function and meet the following criteria:
+Inadequate performance status/organ function.
+Demonstrate adequate organ function
+Adequate organ function
+Adequate organ function with the following laboratory results during screening (within 21 days) and immediately before study drug administration on Cycle 1 Day 1:
+Adequate hematologic and end-organ function
+Adequate baseline organ function within 14 days prior to the first dose of enzalutamide and/or CORT125281
+ORGAN FUNCTION AND PERFORMANCE STATUS CRITERIA:
+Inadequate performance status/organ function.
+Adequate organ function at screening
+Adequate organ function defined as: Bone Marrow:
+Subject has adequate bone marrow and organ function as shown by:
+Has adequate organ function
+Has adequate organ function within 7 days before enrollment
+Subject has adequate organ function as determined by the following laboratory values:
+Adequate organ function
+Adequate hematologic and organ function as confirmed by laboratory values
+Adequate hematologic and end-organ function
+-  Has adequate organ function.
+Demonstrate adequate organ function obtained within 14 days prior to randomization and analyzed by the central laboratory.
+Demonstrate adequate organ function
+The participant has adequate hematologic, organ, and coagulation function ?2 weeks (14 days) prior to first dose of study drug:
+Adequate organ function as defined by the following criteria:
+Adequate hematologic and organ function as confirmed by laboratory values
+Adequate organ system function.
+Must have adequate organ function defined as:
+Adequate haematologic and end-organ function
+Have adequate organ function.
+Adequate hematologic and end-organ function
+Adequate organ function per protocol-defined criteria.
+Evidence of insufficient organ function as determined by the protocol.
+Adequate organ function as appropriate for the disease under study. All screening laboratory tests should be performed within 10 days of treatment initiation.
+Adequate organ and marrow function
+Have adequate hematologic, organ and coagulation function within 2 weeks (14 days) prior to enrollment.
+Candidate for pembrolizumab (as determined by physician, and adequate organ function)
+Adequate organ function and blood cell counts.
+Adequate organ function.
+Have adequate organ function (all screening labs should be performed within 15 days prior to study treatment):
+HEALTHY SUBJECT: Have adequate organ function
+Demonstrate adequate organ function, all screening labs should be performed within 14 days prior to registration
+Adequate organ function.
+Adequate organ function confirmed at Screening and within 10 days of initiating treatment, as evidenced by:
+Adequate organ function as defined by the following criteria:
+Adequate organ function within 14 days of study registration
+Adequate hematologic and organ function
+Patients must have adequate organ and bone marrow function within 14 days prior to registration, as defined by: leukocytes >= 2,000/mcL
+Subjects with adequate organ and bone marrow function as defined below:
+Patients must have adequate organ and marrow function as determined by the treating oncologist
+Must have adequate organ function, as defined by the following:
+Adequate organ function.
+Patient has adequate organ function at Baseline
+Adequate organ function as defined by:
+Adequate organ and bone marrow function
+Adequate organ and neurologic function
+Has adequate organ function including:
+Adequate organ function
+Adequate organ function within 28 days prior to enrollment, as defined by the following criteria:
+Subjects must have adequate organ and marrow at screening as defined below:
+Have adequate organ function.
+Demonstrate adequate organ function; all screening laboratory tests should be performed within 7 days of treatment initiation
+Patients must have adequate organ and bone marrow function =< 14 days prior to registration, as defined below:
+Persons who do not meet the age and organ function criteria specified above
+The patient has adequate organ and marrow function per protocol
+Adequate organ function
+Adequate organ function as defined below:
+Adequate organ function as defined below:
+Have adequate organ function.
+Potentially eligible for reduced intensity conditioning based on known organ function (formal organ function testing may occur after consent)
+Have adequate organ function.
+Adequate organ and marrow function
+Demonstrate adequate organ function, all screening labs should be performed within 10 days of study drug administration
+Patients must have adequate bone marrow and organ function.
+Adequate organ function as defined by all the following criteria:
+Patients must have adequate organ function at baseline as defined below: • Adequate liver function (within 7 days of crenolanib commencement), as determined by:
+Adequate hematologic and end organ function obtained within 2 weeks prior to first dose of study drug
+Patient has adequate organ function, as indicated by the following laboratory values
+Adequate organ function
+Adequate organ functions
+Adequate organ function as defined by the following criteria:
+Organ function:
+Patients must have adequate organ function
+Adequate organ function within 14 days of registration
+Adequate organ function
+Adequate organ function as determined by the following laboratory values:
+Adequate other organ functions
+Acceptable end-organ function, except for documented exclusions for organ function compromise due to ALL itself
+Adequate organ function
+Adequate normal organ and marrow function
+Adequate organ and bone marrow function defined by routine testing
+Adequate organ and marrow function as determined by medical oncology evaluation
+All patients must have adequate organ function defined as:
+Organ Function Requirements:
+Adequate organ function as outlined below (unless due to leukemia)
+Adequate organ function
+Adequate organ function including:
+Adequate organ function
+All organ function testing should be done within 28 days of study registration
+Adequate bone marrow and organ function defined by laboratory values
+Adequate bone marrow and organ function
+Adequate organ and marrow function
+Have adequate organ function.
+Inadequate performance status/ organ function
+Adequate organ and bone marrow function
+Adequate organ function.
+Adequate End organ function
+Has adequate organ function as defined by:
+Adequate organ function
+Patient has adequate organ function
+Patients must have adequate organ function
+Adequate normal organ and marrow function as defined below (must be done within 30 days prior to enrolment):
+Adequate organ system function within 14 days of baseline:
+Poor organ function.
+Adequate organ and marrow function
+Has adequate organ function
+Adequate organ function
+Adequate organ function as defined in the protocol
+Patients must have normal organ function as defined below:
+Adequate organ function
+Other serious co-morbid illness or compromised organ function
+Organ function characterized by ? Grade 1
+Has adequate organ function as defined by the following criteria:
+Have adequate organ function
+Patients must have normal organ function as defined below:
+Adequate non-hematologic organ system function, defined by:
+Patients must have adequate organ and system function.
+Subjects who have adequate organ functions
+Organ function must be adequate as follows:
+Adequate bone marrow and organ function as assessed by the laboratory tests performed within 7 days before of treatment initiation.
+have inadequate organ function per protocol
+Has adequate organ function
+Adequate organ function.
+Adequate organ function
+Adequate organ and marrow function, defined per protocol
+Patient must meet the organ function and system function requirements as stated in the protocol
+Have adequate organ function defined by the protocol.:
+Adequate organ function as evidenced by:
+Adequate hematologic and end organ function
+Adequate organ function as determined by following laboratory parameters:
+Adequate end-organ function
+Adequate end-organ function, as determined by laboratory tests obtained within 28 days prior to the first dose of study drug
+Patients must have organ function as defined below:
+Acceptable organ and marrow function during the Screening Period as defined by the\n             protocol.
+Demonstrate adequate organ function per institutional guidelines for high-dose melphalan and autologous transplant at the time of enrollment
+Adequate organ function
+Adequate hematologic and end-organ function
+Adequate hematologic and organ function as confirmed by laboratory values
+-  The participant has adequate organ function:
+Adequate organ function as defined by study-specific laboratory tests
+Demonstrates adequate organ function.
+Adequate organ function, as defined by the following criteria:
+Adequate bone marrow and organ function
+Adequate organ function.
+Adequate organ function
+Adequate hematological and organ function, confirmed by lab values
+Adequate organ function per protocol-defined criteria.
+Demonstrates adequate organ function.
+adequate organ function
+Adequate organ function
+Adequate organ function
+Adequate organ function defined as:
+Adequate hematologic and end-organ function.
+Adequate hematological and organ function as confirmed by laboratory values
+Adequate organ function:
+Inadequate organ function including:
+Adequate hematologic and end organ function
+Adequate organ function prior to registration
+Adequate hematologic and organ function within 28 days prior to initiation of study treatment
+Adequate hematologic and end-organ function test results
+Adequate organ function
+Adequate organ function
+Adequate organ function
+Demonstrates adequate organ function
+Demonstrates adequate organ function.
+Adequate organ function defined as follows:
+Adequate organ function
+Has adequate organ function
+Adequate organ and marrow function
+Have adequate organ function.
+Has adequate organ function as defined by protocol defined labs.
+Adequate organ function as shown by:
+Adequate organ function defined as:
+Adequate hematologic and end organ function
+Hemodynamically stable and adequate organ function
+Poor organ function.
+Adequate organ function
+Inadequate organ function including:
+Adequate organ and marrow function
+Adequate organ function.
+Demonstrates adequate organ function.
+Adequate organ function
+Adequate hematologic and end organ function, confirmed by laboratory results obtained within 28 days prior to initiation of study drug
+Inadequate organ function including:
+Adequate organ function
+Adequate hematologic and end-organ function
+Adequate organ function as defined in the protocol
+Adequate organ function
+Chemistry panel obtained 30 days prior to registration on study, with adequate organ function
+Have adequate organ function.
+Adequate hematologic and end organ function
+Adequate hematologic and end organ function
+Adequate organ and bone marrow function determined within 14 days prior to enrollment defined as:
+Adequate organ function
+Adequate hematologic and organ function as confirmed by laboratory values
+Adequate organ function at baseline as defined below. All laboratory assessments should be performed within 10 days of treatment initiation.
+Adequate hematologic and end organ function
+Have adequate organ function, as defined by the study protocol.
+Subject must have adequate organ function as indicated by the following laboratory values in the table below:
+Adequate organ function
+Has adequate organ function.
+Adequate hematologic and end-organ function within 28 days prior to treatment initiation
+Subjects must have adequate organ and marrow function as defined below:
+Have organ and marrow function at the screening and pre-dose visits as defined by:
+Patients must have adequate organ function:
+Must have adequate organ function as demonstrated by the following:
+Adequate organ function as defined by the following criteria:
+Patients must have normal organ and marrow function as defined below:
+Adequate Organ Function
+Adequate organ function per protocol-defined criteria.
+Adequate organ function per protocol-defined criteria.
+Adequate organ function per protocol-defined criteria.
+Adequate organ and marrow function
+Adequate organ function defined as follows:
+Adequate hematologic and end-organ function
+have adequate organ function
+Adequate organ function
+Have adequate organ function.
+Demonstrates adequate organ function
+Has adequate organ function
+Adequate organ function as defined below:
+Organ Function
+Patients must have normal organ and marrow function documented within 7 days of study enrollment as defined below:
+Inadequate organ function
+Demonstrate adequate organ function as detailed above
+Adequate hematologic and end organ function
+Patient has adequate bone marrow and organ function
+Subjects must have adequate organ function as indicated by the following laboratory values.
+Have adequate organ functions.
+Adequate hematologic and end organ function
+Have adequate organ function.
+Adequate organ and marrow function
+Patient has adequate bone marrow and organ function
+Adequate organ function
+Have adequate organ function
+Adequate baseline organ function.
+Adequate hematologic and organ function within 14 days before the first study treatment
+Adequate organ function
+Adequate organ function
+Have adequate organ function including:
+Have adequate organ function
+Has adequate organ function as defined by protocol
+Adequate organ and marrow function, resolution of all toxic effects of prior therapy or surgical procedures
+Adequate organ and marrow function
+Organ Function Requirements - Subjects must have adequate organ functions as defined below:
+Organ function requirements are not required for enrolled patients who are stage I, PFH and will not be receiving chemotherapy
+Adequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to the first study treatment (Cycle 1, Day 1):
+Subject has adequate organ function as determined by the following laboratory values:
+Adequate baseline organ function, as demonstrated by the following:
+Patients must have adequate organ and bone marrow function
+Adequate organ function defined as:
+Adequate organ function
+Patients must have adequate organ and bone marrow function within 14 days prior to registration, as defined below:
+Demonstrated adequate organ function within 14 days of treatment initiation.
+Have adequate organ function, with all screening labs performed within 7 days of treatment initiation.
+Have adequate organ function.
+Adequate organ function defined as follows: System and Laboratory Values: Hematologic
+Life expectancy ? 12 weeks. 7. ECOG PS of 0 or 1 8. Adequate organ and bone marrow function 9. Ability to undergo during screening a tumor biopsy that is adequate for biomarker analysis.
+Has adequate organ function
+Adequate organ function
+Adequate organ function including:
+Adequate organ function
+Demonstrate adequate organ function, all screening labs should be performed within 14 days of treatment initiation
+Adequate organ function.
+Adequate organ function
+The participant has adequate organ function.
+The participant has adequate organ function, including:
+Demonstrate adequate organ function, all screening labs should be performed within 6 weeks of treatment initiation
+Adequate organ and bone marrow function within the 21 days prior to randomization defined by:
+Subject has adequate organ function.
+Adequate organ function
+Adequate organ function
+Adequate organ function
+Adequate organ function
+Adequate organ function
+Adequate organ and marrow function; Evidence of post-menopausal status or negative urinary or serum pregnancy test.
+Adequate hematologic and end organ function
+Adequate organ function
+Adequate organ function
+Adequate organ function
+Adequate baseline organ function as defined below
+Adequate organ and marrow function
+Adequate bone marrow and organ function
+Adequate hematologic and end organ function Cohort 2-Specific Inclusion Criteria
+Adequate organ function
+Have adequate organ and hematologic function, as determined by:
+Adequate organ function
+Adequate organ function including:
+Adequate organ function
+Adequate hematologic and end organ function
+Adequate organ and marrow function , as defined below:
+Adequate organ function within 14 days of dosing
+Adequate organ function
+Adequate hematologic and end-organ function
+Has adequate organ function
+Adequate organ functions
+Adequate organ function, defined as:
+Adequate organ function according to protocol-defined criteria
+Inadequate organ function as described
+Adequate bone marrow, organ function, cardiac and laboratory parameters
+Adequate major organ system function
+Adequate organ function including:
+Adequate organ function including:
+Adequate bone marrow, organ function, cardiac and laboratory parameters
+Have adequate organ function;
+Adequate end organ function as defined by:
+Adequate organ and marrow function.
+Have adequate organ function as defined by specified laboratory values
+Adequate organ function
+Patients must have normal organ and marrow function as defined below:
+Patients must have adequate hematologic and organ function.
+Adequate baseline organ function
+Have adequate organ system function
+Adequate organ function as defined by the following criteria:
+Patients with adequate organ function as measured by:
+Adequate hematologic and end organ function
+Adequate organ function
+Have adequate organ and bone marrow function.
+Has adequate organ function
+Adequate organ and marrow function.
+The participant has adequate organ function.
+Adequate organ function as evidenced by the following laboratory findings:
+Adequate organ function within 10 days of Day 1
+Has adequate organ function
+Demonstrates adequate organ function.
+Adequate baseline organ function.
+Have adequate organ function (all screening labs should be performed within 15 days prior to treatment initiation):
+Adequate organ function within 3 weeks prior to first study drug administration as evidenced by:
+Adequate organ function per blood work
+Adequate organ function
+Patients must have adequate organ function as indicated by the following laboratory values:
+End-organ function not appropriate for transplantation
+Adequate organ function defined as follows:
+Other serious co-morbid illness or compromised organ function
+Patient must meet the organ function requirements as stated in the protocol.
+Adequate organ function as shown by:
+Adequate organ function, demonstrated by the following laboratory values:
+Adequate baseline organ function
+Adequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to the first study treatment (Cycle 1, Day 1)
+Have adequate organ function
+Patients must have adequate organ and marrow function as defined below
+Adequate organ function and baseline laboratory values
+Subject has adequate organ function.
+Adequate organ function
+Adequate organ function defined as follows:
+Adequate organ function.
+Adequate organ function including:
+Has adequate organ function, before the first dose of study drug.
+Adequate organ function.
+Adequate organ function including the following:
+Adequate organ function defined as follows:
+Adequate organ function defined as:
+Adequate organ function defined as follows:
+Adequate organ and marrow function
+Adequate organ and hematological function as evidenced by the following laboratory values within 14 days before enrollment:
+Adequate organ and hematological function as evidenced by the following laboratory values within 14 days before enrollment:
+Adequate organ function defined as follows:
+Adequate bone marrow function and organ function
+Adequate organ system function.
+Patients must have normal organ and marrow function as defined below:
+Adequate organ function
+Adequate organ function
+Adequate hematologic and end-organ function
+Patient has adequate bone marrow and organ function.
+Demonstrate adequate organ function.
+Adequate organ and marrow function
+Adequate organ function
+Acceptable organ and marrow function ?21 days prior to registration:
+Adequate hematologic and end-organ function
+Acceptable organ function as evidenced by the following:
+Adequate organ function.
+Adequate hematologic and organ function within 14 days before the first study treatment
+Adequate organ and marrow function
+Have adequate organ function.
+Have adequate organ function.
+Adequate hematologic and end organ function
+Have adequate organ function.
+Adequate hematologic and end-organ function
+Adequate organ function as defined below:
+Adequate hematologic and end-organ function
+Adequate hematologic and end-organ function
+Adequate organ function as determined by the following laboratory results, within 28\n             days prior to randomization
+Adequate hematologic and organ function as confirmed by laboratory values at Screening:
+Adequate hematologic and end-organ function
+Adequate organ and marrow function
+Patients must have normal organ and marrow function as defined below:
+Adequate organ function defined as follows:
+Adequate organ function defined as below:
+Adequate organ function within 14 days of study entry
+Adequate organ and marrow function
+Adequate organ function
+Adequate organ function at baseline:
+Have adequate organ function.
+Adequate organ function
+Must have normal organ and marrow function reported within 14 days prior to randomization
+Adequate organ function, including the following:
+Adequate hematologic and end-organ function
+Adequate baseline organ function as defined in the protocol.
+Have adequate bone marrow reserve and organ function at screening as follows:
+Adequate organ and marrow function
+Adequate organ function as defined below:
+For all tumor types, adequate organ and marrow function, as defined below:
+Have adequate organ function as defined by specified laboratory values
+Inadequate organ function as defined on laboratory tests
+Must have adequate organ function as defined by the following screening values (Retesting of borderline screening organ function and treatment with blood transfusions, growth factors etc. will be allowed):
+Adequate bone morrow and organ function
+Adequate hematologic and end-organ function
+Adequate hematologic and end-organ function
+The subject has poor organ and marrow function as defined in the protocol.
+Adequate bone marrow and organ function
+Adequate hematologic and end organ function
+Adequate organ function:
+Previously treated; NOTE: no limit to prior therapy provided there is adequate residual organ function
+Patients must have adequate organ function, as defined by the following parameter
+Subject must have normal organ and marrow function as defined below:
+Adequate organ function including:
+Patients must have normal organ and marrow function as defined below:
+Patient has adequate bone marrow and organ function.
+Patients must have normal organ and marrow function
+Adequate baseline organ function.
+Adequate organ function
+Adequate hematologic and organ function within 14 days prior to treatment initiation
+Adequate hematologic and end-organ function
+Adequate organ or bone marrow function
+Adequate bone marrow and organ function
+Adequate organ function as defined by:
+Adequate organ and marrow function:
+Adequate organ function
+Organ function </= grade 1.
+Adequate organ function
+Adequate hematologic and end organ function
+Patient has adequate bone marrow and organ function
+Adequate organ and marrow function
+Inadequate hematological, biochemical or organ function
+Adequate organ function;
+Adequate hematologic and end-organ function
+Have adequate organ function as defined by specified laboratory values
+Adequate organ function
+Adequate organ system function determined within 14 days prior to first dose of study treatment.
+Adequate organ and bone marrow function
+Adequate organ function.
+At the time of the CMV specific T cell infusion, the recipient must have adequate organ function as indicated by < grade 3 across all organ systems except for hematologic toxicity
+Adequate organ and marrow function
+Patients must have adequate organ function, as defined by the following parameters:
+Have adequate organ function, including:
+Adequate organ function.
+Adequate organ system function.
+Adequate organ and bone marrow function as assessed by laboratory tests
+Normal organ function tests including Creatinine
+Normal organ function tests including Bilirubin
+Normal organ and marrow function.
+Other serious co-morbid illness or compromised organ function.
+Patients with adequate organ function as measured by:
+Adequate hematologic and end-organ function
+Adequate bone marrow and organ function
+Patients must have adequate organ function within 14 days prior to registration, as defined below:
+Adequate hematologic and end organ function
+Has adequate organ function as determined by laboratory tests
+adequate organ function
+Adequate organ function, including the following:
+Adequate other organ function at screening and enrollment.
+Adequate other organ function at screening and enrollment.
+Subject must have adequate organ function as indicated by the laboratory values below:
+Participants must have adequate organ function, including the following:
+Adequate bone marrow and organ function
+Life expectancy of at least 12 weeks. - Adequate organ function
+Patients are eligible regardless of organ/marrow function
+All organ function testing should be done within 28 days of study registration
+Participants must have adequate organ and marrow function to proceed to transplant
+Regarding non-hematologic organ function, no specific criteria for non-hematologic organ function are specified; however, if moderate-to-severe (major) organ function is present, such should be discussed with the PI, as various degrees of non-hematologic organ dysfunction may compromise either (or both) toxicity and response evaluations; also, if there is concern regarding potential reversibility of any specific organ dysfunction, this issue should also be addressed by consultation with an appropriate sub-specialist
+Adequate bone marrow and organ function as determined by the consenting/enrolling investigator
+Adequate hematologic and end organ function
+Adequate hematologic, cardiac, and end-organ function
+Adequate organ and marrow function.
+Adequate hematologic and end-organ function
+No organ and marrow function requirements
+Adequate organ function, as defined by the following criteria (per central or local laboratory values):
+No restrictions will be made based on organ or marrow function
+Patients must have adequate organ functions at the time of registration:
+Adequate organ function as determined by the following laboratory values:
+Organ Function Requirements: Subjects must have adequate liver function as defined by:
+Normal organ and marrow function
+Organ Function Requirements: Subjects must have adequate liver function as defined by:
+Adequate hematologic and end-organ function
+Acceptable pre-study organ function during screening defined as:
+Adequate organ function
+Adequate organ function including:
+Requirements for organ and marrow function are not applicable to this study, but function will need to be sufficient to undergo planned therapy
+No requirements for organ and marrow function
+Has adequate organ function.
+Subject must have adequate organ function as defined in the protocol.
+Patients must have adequate organ and bone marrow function 10 days prior to registration, as defined below:
+Adequate bone marrow and organ function as defined as:
+Has adequate organ function
+Adequate organ function including:
+Adequate baseline organ function:
+Have adequate organ function
+Adequate organ function
+Adequate organ function for patients receiving crizotinib therapy as defined by the following criteria: Bone marrow function
+Normal organ and marrow function within limits as defined below:
+Organ function requirements:
+Adequate organ function determined within 14 days prior to enrollment
+The patient has adequate organ and marrow function as follows:
+Adequate end organ function as defined by:
+Adequate organ function.
+Subjects must have normal organ and marrow function as defined below:
+Adequate organ and bone marrow function
+Adequate hematologic and end organ function
+Must have adequate organ function, including the following:
+Adequate organ function as determined by the investigator
+Subjects must have normal organ and marrow function as defined below:
+Adequate organ and bone marrow function
+Adequate organ and marrow function
+Adequate organ function within 7 days prior to enrollment, as defined by the following criteria:
+Demonstrates adequate organ function, within 10 days prior to the start of study drug.
+Adequate hematologic and end-organ function
+Adequate organ system function, defined as follows:
+Adequate organ function as per protocol.
+Has adequate organ function
+Adequate organ function
+Evidence of adequate organ function by standard laboratory tests.